Related Experiment Video

Updated: Jan 2, 2026

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

688

MiR-7-5p suppresses tumor metastasis of non-small cell lung cancer by targeting NOVA2

Haiping Xiao1

  • 1Thoracic Surgery Department, General Hospital of Southern Theater Command, Guangzhou, 510010 PLA China.

Cellular & Molecular Biology Letters
|December 14, 2019
PubMed
Abstract

Insights

MicroRNA-7-5p (miR-7-5p) suppresses non-small cell lung cancer (NSCLC) metastasis by targeting NOVA2. Restoring miR-7-5p levels may improve NSCLC treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer death globally.
  • Distant metastasis significantly hinders NSCLC treatment efficacy.
  • The tumor-suppressive role of microRNA-7-5p (miR-7-5p) is established in other cancers, but its function in NSCLC remains unclear.

Purpose of the Study:

  • To investigate the role of miR-7-5p in non-small cell lung cancer (NSCLC) progression.
  • To elucidate the molecular mechanism underlying miR-7-5p's function in NSCLC.

Main Methods:

  • Quantitative real-time PCR (qPCR) and cell-based assays (MTT, migration, invasion) assessed miR-7-5p's impact on NSCLC cell behavior in vitro.
  • A tumor xenograft model evaluated miR-7-5p's effect on metastasis in vivo.
  • Dual-luciferase reporter assays, NOVA2 overexpression, and western blotting explored the underlying molecular mechanism.

Main Results:

  • MiR-7-5p was found to be downregulated in NSCLC tissues and cell lines.
  • MiR-7-5p inhibited proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) markers in vitro and in vivo.
  • MiR-7-5p suppresses NSCLC metastasis by directly targeting neuro-oncological ventral antigen 2 (NOVA2).
  • Overexpression of NOVA2 counteracted the inhibitory effects of miR-7-5p in lung cancer cells.

Conclusions:

  • MiR-7-5p acts as a suppressor of non-small cell lung cancer (NSCLC) metastasis.
  • Therapeutic strategies targeting miR-7-5p hold potential for improving NSCLC treatment outcomes.
Keywords:
MetastasisNeuro-oncological ventral antigen 2 (NOVA2)Non-small cell lung cancer (NSCLC)SuppressmicroRNA-7-5p (miR-7-5p)

More Related Videos

The Soft Agar Colony Formation Assay08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

113.4K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.8K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K